Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.

ABSTRACT:

Aims

To investigate glycaemic control in Chinese adults with type 2 diabetes (T2D) initiating, or switching to insulin degludec/insulin aspart (IDegAsp), a co-formulation of basal, and bolus insulin, in a real-world setting.

Materials and methods

A 20-week, prospective, single-arm, open-label, non-interventional study was conducted in Chinese adults with T2D initiating, or switching to IDegAsp after anti-hyperglycaemic treatment with oral antidiabetic drugs (OADs), other insulins, or glucagon-like peptide-1 receptor agonists. The primary endpoint was a change in HbA_1c from baseline to end of the study; the secondary endpoints included a change in fasting plasma glucose and Diabetes Treatment Satisfaction Questionnaire (DTSQ) score.

Results

Significant reduc

SUBMITTER: Guo L 

PROVIDER: S-EPMC11802397 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature